

Indication	<p>Monotherapy for the treatment of patients with:</p> <ul style="list-style-type: none"> • previously untreated chronic lymphatic leukaemia (CLL) or small lymphocytic lymphoma (SLL) which has a 17p deletion and/or TP53 mutation • Patients with chronic lymphatic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who have had at least one previous line of treatment. <p>NB the patient has not received any previous Bruton's kinase inhibitor for CLL/SLL unless acalabrutinib was previously commenced via an AstraZeneca early access scheme or ibrutinib has had to be stopped as a consequence of dose-limiting toxicity and in the clear absence of disease progression.</p>
Treatment Intent	Disease modification.
Frequency and number of cycles	<p>Repeat every 28 days.</p> <p>Continue until disease progression or unacceptable toxicity or patient choice to stop treatment</p> <p>A formal medical review as to whether treatment with acalabrutinib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment</p>
Monitoring Parameters pre-treatment	<ul style="list-style-type: none"> • Check virology status prior to start of treatment. • Monitor FBC, U&Es and LFTs at each cycle. • ECG baseline in patients with cardiac history. • Hepatic impairment: Avoid administration of acalabrutinib in patients with severe hepatic impairment (Child-Pugh C or total bilirubin >3xULN and any AST). Dose modifications are not required for patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B, or total bilirubin between 1.5-3x ULN and any AST), however patients with moderate impairment should be monitored closely for signs of toxicity. • Renal impairment: No dose adjustment in mild to moderate renal impairment (CrCl\geq30ml/min). No data in patients with severe renal impairment (CrCl<30ml/min). Treatment should only be administered in patients with severe renal impairment only if the benefit outweighs the risk and these patients should be monitored closely for signs of toxicity. • Management of adverse reactions and dose adjustments: <ul style="list-style-type: none"> ○ For Grade 3 or greater non- haematological toxicities, Grade 3 thrombocytopenia (PLT 25-49) with bleeding, Grade 4 thrombocytopenia (<25) or Grade 4 neutropenia (<0.5) lasting longer than 7 days (supporting neutrophil growth factors could be considered) the recommended dose adjustments are: <ul style="list-style-type: none"> ▪ First and Second occurrence - Interrupt acalabrutinib. Once toxicity has resolved to Grade 1 (neuts \geq1, platelets \geq 75) or baseline level, acalabrutinib may be resumed at 100 mg approximately every 12 hours. ▪ Third occurrence - Interrupt acalabrutinib. Once toxicity has resolved to Grade 1 (neuts \geq1, platelets \geq 75) or baseline level, acalabrutinib may be resumed at a reduced frequency of 100 mg once daily. ▪ Fourth occurrence - Discontinue acalabrutinib. ○ Haemorrhage: Use with caution with antithrombotic agents and consider additional monitoring for signs of bleeding when concomitant use is medically necessary. Consider withholding acalabrutinib for 3-7 days pre and post-surgery depending on the type of surgery and the risk of bleeding. ○ Progressive multifocal leukoencephalopathy (PML): PML has been reported in patients receiving acalabrutinib. Patients should be monitored for new or

Protocol No	CLL-036	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	1	Written by	M.Archer
Supersedes version	New protocol	Checked by	C.Waters M.Capomir
Date	06.01.21	Authorising consultant (usually NOG Chair)	N.Heeney

	<p>worsening neurological, cognitive or behavioural changes. All treatment should be held if PML is suspected and permanently discontinued if PML is confirmed.</p> <ul style="list-style-type: none"> ○ Sun exposure: Monitor patients for skin cancers and advise protection. ○ Monitor for symptoms of arrhythmia (e.g., palpitations, dizziness, syncope, dyspnoea) and manage as appropriate. The risk of arrhythmia may be increased in patients with cardiac risk factors, hypertension, previous arrhythmias, and acute infection. ● Common drug interactions/cautions (for comprehensive list refer to BNF/SPC): <ul style="list-style-type: none"> ○ Avoid concomitant use of strong CYP3A inhibitors (e.g ketoconazole, ritonavir, clarithromycin, itraconazole, voriconazole, posaconazole), if the short-term use of a strong CYP3A inhibitor cannot be avoided, interrupt treatment with acalabrutinib. If a moderate CYP3A inhibitor is required monitor closely for adverse reactions. ○ Avoid concomitant use with strong CYP3A inducers (e.g. phenytoin, rifampicin, and carbamazepine). ○ Avoid grapefruit, grapefruit juice and seville oranges. ○ Concomitant use of preparations containing St John's Wort should be avoided. ○ Warfarin or other vitamin K antagonists should not be administered concomitantly. ○ Concomitant Use with Gastric Acid Reducing Agents: Proton Pump Inhibitors: Avoid concomitant use. H2-Receptor Antagonists: Take acalabrutinib 2 hours before taking a H2-receptor antagonist or 10 hours after. Antacids: Separate dosing by at least 2 hours. ● Missed dose: If the dose has been missed by less than 3 hours the patient should take their usual dose. If more than 3 hours have passed, the patient should be instructed to miss that dose and take next dose of acalabrutinib at the usual time. Do not take extra capsules to make up for the missed dose. ● For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet. ● Acalabrutinib may cause fatigue and dizziness; patients should be advised to avoid driving or operating machinery if affected.
References	SPC accessed online 11.12.20 Blueteq form accessed online 14.12.20 ARIA regimen compassionate use acalabrutinib.

NB For funding information, refer to CDF and NICE Drugs Funding List

Protocol No	CLL-036	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	1	Written by	M.Archer
Supersedes version	New protocol	Checked by	C.Waters M.Capomir
Date	06.01.21	Authorising consultant (usually NOG Chair)	N.Heeney

Repeat every 28 days.

TTO	Drug	Dose	Route	Directions
	ACALABRUTINIB	100mg	PO	BD Should be swallowed whole with a glass of water. Do not open, break, or chew capsules. Should be taken either 2 hours before or 2 hours after any antacid medication or two hours before H2 receptor antagonists.
	Allopurinol	300mg	PO	OD. Cycle 1 only.
	Metoclopramide	10mg	PO	Take 10mg up to 3 times a day as required. Do not take for more than 5 days continuously.
	Loperamide	2mg-4mg	PO	Take two capsules (4mg) after first loose stool, then one capsule (2mg) after each loose stool when required. (Maximum 16mg per day). Dispense on Cycle 1 only, then prescribe as required.
	Co-trimoxazole	480mg	PO	BD on Mondays, Wednesdays and Fridays.
	Aciclovir	400mg	PO	BD
	Consider the use of prophylactic anti fungals. Caution drug interaction with some anti fungals.			

Protocol No	CLL-036	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	1	Written by	M.Archer
Supersedes version	New protocol	Checked by	C.Waters M.Capomir
Date	06.01.21	Authorising consultant (usually NOG Chair)	N.Heeney